IPO
Two months after Centessa Pharmaceuticals launched following the merger of 10 private biotech companies, the company is already eying a $100 million splash on the Nasdaq stock exchange.
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
Recursion Pharma is getting bigger and bigger with its new public offering. The Recursion Pharmaceuticals IPO is anticipated to bring approx $306 million.
The wave of biopharma companies going public continues with two more companies setting sights on publicly trading on a stock exchange. Reneo Pharmaceuticals and VectivBio will both begin trading on the Nasdaq this week.
At this time Vaccitech hasn’t priced its offering, although the report suggests they might sometime this month.
April springs up with showers of cash for these life sciences companies.
The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo.
This morning, Ikena Oncology, Design Therapeutics and Edgewise Therapeutics began trading on the exchange.
Several new initial public offering (IPO) announcements have been made by international and U.S.-based biopharmaceutical and biotechnology companies in the past couple of days.
This week, four companies set sights on listing their shares on the stock market in hopes of raising significant funds to support the development of their pipelines and businesses.
PRESS RELEASES